Search
0 results

No results, please enter a search term above

HAI/AR Surveillance Data Reports

The Philadelphia Department of Public Health (PDPH) HAI/AR Program conducts year-round surveillance for multiple drug-resistant organisms of public health concern by collecting clinical and laboratory information from healthcare facilities. The HAI/AR Program also monitors and tracks numerous healthcare-associated infections and metrics that are reported into the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN), the nation’s most widely used healthcare-associated infections tracking system.

Posting of this data is intended for the purpose of promoting the health of Philadelphia residents and for providing a reference to healthcare providers citywide to inform practice in their own institutions. PDPH attempts to post timely and reliable information, but due to the limitations of the surveillance systems used to generate these data, we cannot guarantee that all data is complete or up-to-date.

Quarter 4: October 2020 - December 2020

Carbapenem-resistant Enterobacteriaceae (CRE): October - December 2020

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

30 (65%)

Non-CP CRE

8 (17%)

CP Status Pending / Not Tested

8 (17%)

Total Confirmed CRE Cases

46

Quarter 3: July 2020 - September 2020

Carbapenem-resistant Enterobacteriaceae (CRE): July - September 2020

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

31 (53%)

Non-CP CRE

22 (38%)

CP Status Pending / Not Tested

5 (9%)

Total Confirmed CRE Cases

58

Quarter 2: April 2020 - June 2020

Carbapenemase-Producing (CP) Status of Confirmed Cases: April - June 2020

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

17 (27%)

Non-CP CRE

4 (6%)

CP Status Pending / Not Tested

42 (67%)

Total Confirmed CRE Cases

63

Epidemiological Characteristics of CRE Cases (n=63)

Characteristics

Yes

No

Unknown

Philadelphia Resident

51 (81.0)

12 (19.0)

0 (0.0)

LTCF Resident

11 (17.5)

5 (7.9)

47 (74.6)

Invasive Device(s)

22 (34.9)

5 (7.9)

36 (57.1)

Quarter 1: January 2020 - March 2020

Carbapenemase-Producing (CP) Status of Confirmed Cases: January - March 2020

Carbapenemase-Producing (CP) Status of Confirmed Cases

Cases, n (%)

CP-CRE

35 (55%)

Non-CP CRE

10 (16%)

CP Status Pending / Not Tested

19 (30%)

Total Confirmed CRE Cases

64